Evidence map›Paper›PMID 41957123›Full record

ReviewEye (London, England)2026

Retinopathy caused by a primary immune regulatory disorder - the spectrum of AIRE-associated retinopathy: case series and literature review.

Mohammad Anas, Andrew C Browning, Siying Lin, Omar A Mahroo, Andrew R Webster, Margaret Reynolds, Tatyana Milman, Ralph C Eagle, Richard Vile, Marc Toso and 4 more

Abstract readReviewCase ReportsMulticenter Study
In one paragraph

Review in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mohammad AnasDepartment of Ophthalmology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.
Andrew C BrowningNewcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0003-1667-8505
Siying LinUCL Institute of Ophthalmology, University College London, London, UK.ORCID http://orcid.org/0000-0003-1122-8396
Omar A MahrooDepartment of Ophthalmology, Guy's & St Thomas' NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0003-1254-0832
Andrew R WebsterUCL Institute of Ophthalmology, University College London, London, UK.
Margaret ReynoldsDepartment of Ophthalmology and Visual Sciences, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-2588-5517
Tatyana MilmanDepartment of Pathology, Wills Eye Hospital, Sidney Kimmel College of Medicine at Thomas Jefferson University, Philadelphia, USA.
Ralph C EagleDepartment of Pathology, Wills Eye Hospital, Sidney Kimmel College of Medicine at Thomas Jefferson University, Philadelphia, USA.
Richard VileDepartments of Molecular Medicine and Immunology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2192-9372
Marc TosoJohn A. Moran Eye Centre, Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, UT, USA.
Gregory S HagemanJohn A. Moran Eye Centre, Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, UT, USA.
Hossein NazariDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, USA.
Erik J Van KuijkDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, USA.
Jose S PulidoDepartment of Ophthalmology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA. jpulido@willseye.org.

Funding

Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.R01CA269384 · NCI · MAYO CLINIC ROCHESTER · PI Richard G. Vile · 2023 to 2026
$1.4M
NCI NIH HHS R01 CA269384
6 · The paper itself

Abstract

BACKGROUND/

objectiveRetinal involvement in autoimmune polyendocrine syndrome type 1 (APS1), a rare monogenic autoimmune disorder caused by mutations in the AIRE gene, is increasingly recognised but remains poorly defined. Prior reports suggest a variable phenotype, ranging from mild changes to severe vision loss, often presumed untreatable. We explored the range of retinal phenotypes associated with AIRE gene deficiency in a multicentre case series of patients with APS1.

methodsWe performed a retrospective case note review of patients with molecularly confirmed APS1 from tertiary ophthalmic centres. Clinical history, multimodal retinal imaging, electrophysiology, genetic data, and treatment regimens were analysed. Histopathology was available in one case postmortem.

resultsRecords were reviewed from five unrelated female patients. Median age was 14 years at onset of ocular involvement and 33 years at most recent follow up. Some findings from two cases have been previously reported. Three distinct pathogenic AIRE variants contributing to biallelic genotypes were observed. Retinal findings ranged from structurally and functionally normal to advanced degeneration. One patient demonstrated sharp zonal atrophy on histopathology. Inflammatory features predominated in two cases, both showing durable vision preservation with periocular or systemic immunomodulation. One patient demonstrated four years of disease stabilisation with rituximab. No consistent genotype-phenotype correlation emerged.

conclusionAIRE-associated retinopathy encompasses a diverse spectrum, from clinically silent to profound degeneration. Early, targeted immunomodulation might preserve vision in selected cases. These findings advocate for ophthalmic surveillance in APS1, and support further investigation into predictive biomarkers and possible tailored immunotherapy in this vision-threatening autoimmune disorder.

Indexed as

Polyendocrinopathies, AutoimmuneRetinal DiseasesTranscription FactorsAdolescentAdultAIRE ProteinElectroretinographyFemaleHumansMutationPhenotypeRetrospective StudiesYoung AdultAIRE ProteinTranscription Factors

Identifiers

PMID41957123
PMCPMC13269743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.